Inactive Instrument

Oragenics Inc Share Price Nyse

Equities

US6840232036

Biotechnology & Medical Research

Sales 2022 0.13 10.94 Sales 2023 0.04 3.13 Capitalization 14.46M 1.2B
Net income 2022 -14M -1.16B Net income 2023 -20M -1.66B EV / Sales 2022 1,18,42,208 x
Net cash position 2022 10.8M 899M Net cash position 2023 3.16M 263M EV / Sales 2023 29,99,79,895 x
P/E ratio 2022
-0.89 x
P/E ratio 2023
-0.61 x
Employees -
Yield 2022 *
-
Yield 2023
-
Free-Float 76.77%
More Fundamentals * Assessed data
Dynamic Chart
Certain Series F Non-Voting, Convertible Preferred Stock of Oragenics, Inc. are subject to a Lock-Up Agreement Ending on 27-MAY-2024. CI
Certain Series B Non-Voting, Convertible Preferred Stock of Oragenics, Inc. are subject to a Lock-Up Agreement Ending on 27-MAY-2024. CI
Certain Series A Non-Voting, Convertible Preferred Stock of Oragenics, Inc. are subject to a Lock-Up Agreement Ending on 27-MAY-2024. CI
Certain Warrants of Oragenics, Inc. are subject to a Lock-Up Agreement Ending on 27-MAY-2024. CI
Certain Options of Oragenics, Inc. are subject to a Lock-Up Agreement Ending on 27-MAY-2024. CI
Certain Common Stock of Oragenics, Inc. are subject to a Lock-Up Agreement Ending on 27-MAY-2024. CI
Certain Series F Non-Voting, Convertible Preferred Stock of Oragenics, Inc. are subject to a Lock-Up Agreement Ending on 27-MAY-2024. CI
Certain Series B Non-Voting, Convertible Preferred Stock of Oragenics, Inc. are subject to a Lock-Up Agreement Ending on 27-MAY-2024. CI
Certain Series A Non-Voting, Convertible Preferred Stock of Oragenics, Inc. are subject to a Lock-Up Agreement Ending on 27-MAY-2024. CI
Certain Warrants of Oragenics, Inc. are subject to a Lock-Up Agreement Ending on 27-MAY-2024. CI
Certain Options of Oragenics, Inc. are subject to a Lock-Up Agreement Ending on 27-MAY-2024. CI
Certain Common Stock of Oragenics, Inc. are subject to a Lock-Up Agreement Ending on 27-MAY-2024. CI
Sector Update: Health Care Stocks Ease Thursday Afternoon MT
Oragenics to Start Phase 2 Concussion Treatment Drug Trial -- Shares Rise MT
Oragenics, Inc. Prepares Intranasal Pharmaceutical, ONP-002, for Phase II Concussion Trial CI
More news
Managers TitleAgeSince
Chief Executive Officer 64 28/12
Director of Finance/CFO 52 07/23/07
Director/Board Member 62 01/20/01
Members of the board TitleAgeSince
Chairman 73 04/10/04
Director/Board Member 63 04/23/04
Director/Board Member 65 30/09/30
More insiders
Oragenics, Inc. is a development-stage company. It is engaged in the research and development of nasal delivery pharmaceutical medications in neurology and fighting infectious diseases. It is focused on nasal delivery of pharmaceutical medications in neurology and fighting infectious diseases, including drug candidates for treating mild traumatic brain injury (mTBI or Concussion), and for treating Niemann Pick Disease Type C (NPC), and proprietary powder formulation and an intranasal delivery device. Its lead product ONP-002 is a fully synthetic, non-naturally occurring neurosteroid, is lipophilic, and can cross the blood-brain barrier to rapidly reduce swelling, oxidative stress and inflammation while restoring proper blood flow through gene amplification. It is also focused on developing medical products that treat brain related illnesses and diseases (the Neurology Assets). Its lead product and focus is on the development and commercialization of ONP-002 for the treatment of mTBI.
Calendar
More about the company